Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal
- PMID: 31307873
- DOI: 10.1016/j.vaccine.2019.07.017
Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal
Abstract
Background: In May 2014, a mass vaccination campaign with four-component meningococcal serogroup B (4CMenB) vaccine was launched in a localized region of Quebec, Canada experiencing high invasive meningococcal B disease endemicity. Active post-marketing surveillance identified several cases of nephrotic syndrome (NS) among ∼49,000 vaccinated individuals aged 2 months to 20 years. We report the epidemiologic investigation of this potential vaccine safety signal.
Methods: Active vaccine safety surveillance was conducted electronically, with participants completing an online questionnaire prompted at 7 days after each dose and 6 months following the last dose. Additional NS cases were sought from provincial hospitalization and emergency room databases.
Results: In the year following the first dose of 4CMenB vaccination, four confirmed NS cases (three hospitalized) were identified among vaccinated children 2-5-years-old with onset several months post-vaccination. None had renal biopsy but given their age, and positive response to steroids, idiopathic NS was presumptively diagnosed. Among vaccinated children 1-9-years-old, the NS incidence in the year post-vaccination was 17.7 per 100,000 (1 per 5650 vaccinees) with an NS hospitalization rate (i.e. excluding the outpatient case) that was 3.6-fold higher (95%CI = 0.7-11.8; p = 0.12) than the rest of the province for the same period, and 8.3-fold greater (95%CI = 1.1-62.0; p = 0.039) than during the eight years preceding the immunization campaign in the affected region.
Conclusion: Active safety surveillance identified an unexpected increase in NS incidence following 4CMenB vaccination. Further epidemiological investigation identified four vaccinated cases in total over a 12 month period of follow up. The greater risk in vaccinees had wide confidence intervals with he lower limit including or just above the nul value, an observation with no or marginal statistical significance. The temporal association with vaccination may be explained by other causes and/or chance clustering of a rare event unrelated to vaccination. To confirm or refute a potential link to vaccination, surveillance in other jurisdictions administering 4CMenB to children 1-9-years-old is needed.
Keywords: 4CMenB; Adverse event; Meningococcal vaccine; Nephrotic syndrome.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.Vaccine. 2018 Dec 18;36(52):8039-8046. doi: 10.1016/j.vaccine.2018.10.095. Epub 2018 Nov 19. Vaccine. 2018. PMID: 30467063
-
Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study.Vaccine. 2016 Jul 25;34(34):4046-9. doi: 10.1016/j.vaccine.2016.06.025. Epub 2016 Jun 11. Vaccine. 2016. PMID: 27302338
-
Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: An ecological study.Vaccine. 2020 Jun 26;38(31):4816-4819. doi: 10.1016/j.vaccine.2020.05.055. Epub 2020 May 29. Vaccine. 2020. PMID: 32482458
-
Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.BioDrugs. 2013 Jun;27(3):263-74. doi: 10.1007/s40259-013-0029-2. BioDrugs. 2013. PMID: 23575646 Review.
-
Emerging experience with meningococcal serogroup B protein vaccines.Expert Rev Vaccines. 2017 May;16(5):433-451. doi: 10.1080/14760584.2017.1308828. Epub 2017 Apr 10. Expert Rev Vaccines. 2017. PMID: 28375029 Review.
Cited by
-
Vaccines and nephrotic syndrome: efficacy and safety.Pediatr Nephrol. 2023 Sep;38(9):2915-2928. doi: 10.1007/s00467-022-05835-4. Epub 2022 Dec 13. Pediatr Nephrol. 2023. PMID: 36512075 Free PMC article. Review.
-
Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.Vaccine. 2022 Jan 21;40(2):247-254. doi: 10.1016/j.vaccine.2021.11.071. Epub 2021 Dec 7. Vaccine. 2022. PMID: 34887130 Free PMC article.
-
Coronavirus disease 2019 (Covid-19) vaccination recommendations in special populations and patients with existing comorbidities.Rev Med Virol. 2022 May;32(3):e2309. doi: 10.1002/rmv.2309. Epub 2021 Oct 22. Rev Med Virol. 2022. PMID: 34677889 Free PMC article. Review.
-
Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.Kidney Int Rep. 2021 Sep;6(9):2292-2304. doi: 10.1016/j.ekir.2021.06.027. Epub 2021 Jul 6. Kidney Int Rep. 2021. PMID: 34250319 Free PMC article.
-
Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR Recomm Rep. 2020 Sep 25;69(9):1-41. doi: 10.15585/mmwr.rr6909a1. MMWR Recomm Rep. 2020. PMID: 33417592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous